🇺🇸 FDA
Patent

US 8716315

Analogs of thalidomide as potential angiogenesis inhibitors

granted A61KA61K31/4035A61K31/454

Quick answer

US patent 8716315 (Analogs of thalidomide as potential angiogenesis inhibitors) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/4035, A61K31/454, A61K31/506, A61K31/513